The association between blood albumin level and cardiovascular complications and mortality risk in ICU patients with CKD

Fengming Huang1†, Jinmao Fan2, Xin Wan1, Huogen Liu1, Yundi Shi1, Hailin Shu1, Ying Liu1, Tongan Lu1, Zhenbin Gong1 and Ling Gu1*

Abstract

Background: Studies involving the association of blood albumin with prognosis in patients with chronic kidney disease (CKD) during intensive care unit (ICU) were scarce.

Aim: We investigated whether reduced blood albumin level independently associated with an increased risk of cardiovascular (CV) complications and 1-year mortality risk in ICU patients with CKD.

Methods: The Medical Information Mart for Intensive Care III (MIMIC-III) database was used. Disease diagnosis and death information among a number of 925 ICU patients with CKD, who have been measured for blood biochemistry, were recorded. Here, multivariable logistic regression Models were structured to evaluate the associations between blood albumin levels (first value on admission, maximum and minimum value during ICU) and risks for CV complications and 1-year mortality among these CKD patients.

Results: In 925 CKD patients, the number of CV complication with heart failure (HF), myocardial infarction (MI) or stroke was 470 (50.8%). 406 (43.9%) patients were dead during the follow-up of 1 year after patients were discharged. Our smooth curve results suggested a curvilinear relation on association between blood albumin level and risk of CV complications. The “inflection point” of blood albumin level that patients were at highest risk of CV complications was 3.4 g/dL. The almost linear relationship with a downward trend was observed on the association between blood albumin level and 1-year mortality risk. We found that reduced blood albumin level contributed to lower risk for CV complications and higher risk for 1-year mortality respectively when blood albumin levels in CKD patients were below 3.4 g/dL. Additionally, albumin therapy had an obvious modifying effect on the independent association, suggesting a possible improved effect of albumin therapy on risk of CV complications and 1-year mortality risk in these CKD patients.

Conclusions: Our study reported that reduced blood albumin levels in CKD patients during ICU were related to lower risk for CV complications and increased risk of 1-year mortality.

Keywords: Albumin, Cardiovascular, Mortality, ICU, Chronic kidney disease

Introduction

Chronic kidney disease (CKD) has been considered to be a common health problem, with an estimated prevalence of 13.4% globally [1]. Although in recent years increased medical resources have been allocated for the CKD treatment, life expectancy was still significantly reduced in
these CKD patients, compared with individuals with normal kidney function [2]. Importantly, cardiovascular (CV) complications remain the leading cause of death among these CKD patients. A previous meta-analysis of 1,371,990 individuals evaluated the association of nondialysis-dependent CKD with the risk for CV events and all-cause mortality, suggesting a dramatic increase in mortality risk after adjusting other confounding factors [3]. Another meta-analysis including more than 1.4 million subjects demonstrated a significant association of higher albuminuria with risk for cardiovascular disease (CVD) [4]. It can be seen that the CVD risk in CKD patients surpasses the risk of reaching end-stage kidney disease [5, 6]. Thus, it is very significant to find predictors of CV complications or mortality risk in patients with CKD.

As a 69 kDa protein, albumin accounts for >50% of serum body’s composition, which plays an important role in various physiological functions in body [7]. Because blood albumin has exhibited many properties including anti-inflammation, antioxidant, anticoagulant, antiplatelet aggregation and colloidal permeation [8], hypoalbuminemia (HAE) has been regarded as an potentially modifiable risk factor for CVD. Existing epidemiological evidence has suggested that reduced blood albumin levels were related to myocardial infarction (MI), atrial fibrillation (AF), heart failure (HF) and stroke [9–13]. For instance, the Atherosclerosis Risk in Communities (ARIC) study involving 14,506 individuals reported a significant association of reduced blood albumin with the prevalence of ischemic heart disease [9]. Framingham Offspring study demonstrated that serum albumin could be considered as an independent risk factor on predicting first MI in the 4506 individuals with a follow-up for 22 years [10]. The Health ABC Study suggested that reduced serum level of albumin was independently linked to the occurrence of new onset HF with preserved ejection fraction [11]. The Copenhagen City Heart Study suggested that reduced serum levels of albumin were significantly related to AF development in women, independent of other confounding factors [12]. The Northern Manhattan Study involving 2986 individuals suggested that reduced serum level of albumin was an independent risk factor on predicting incident of cardioembolic and cryptogenic stroke [13].

HAE is mainly caused by the imbalance between decreased synthesis of blood albumin in the liver and increased catabolism. Malnutrition and inflammation are considered to be the two main causes of HAE. Previous evidence reported that tumor necrosis factor can mediate the chronic consumption of albumin in patients with malignant tumors, resulting in HAE syndrome [14]. Importantly, inflammation and oxidative stress play important roles in the progression of CV complications in patients with CKD [15–17]. Malnutrition is also common, especially in patients with advanced CKD or ICU inpatients. However, studies involving the association of blood albumin with the prognosis in CKD patients during intensive care unit (ICU) were few. Considering these research backgrounds, we obtained 925 ICU patients with CKD from the Medical Information Mart for Intensive Care III (MIMIC-III) database. We investigated whether reduced blood albumin levels (first value on admission, maximum and minimum value during ICU) independently contributed to increased risks for CV complications and 1-year mortality among these CKD patients.

**Materials and methods**

**Study samples**

We performed a retrospective study involving ICU patients from MIMIC-III database with a diagnosis of CKD. Our study was consistent with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement [18]. The institutional review boards (IRB) of Beth Israel Deaconess Medical Center (BIDMC) and Massachusetts Institute of Technology (MIT) approved the project and informed consents were exempted due to all patients’ data were anonymized before the data were obtained. All methods were carried out in accordance with relevant guidelines and regulations [18].

The database that contains clinical information from 46,520 ICU patients from 2002 to 2011, is developed and maintained by the Laboratory for Computational Physiology at MIT [19] and includes clinical data from bedside monitors during ICUs of BIDMC, located in Boston, Massachusetts, USA. ICU nurses verified and recorded the hourly physiological data from the bedside monitors. The database provided demographic characteristics, biochemical examination, intravenous medications and other clinical information. For the purpose of our study, we firstly obtained the data from 2930 patients with CKD. Among these patients, only first ICU admission was included if some individuals had multiple ICU admission records. The disease diagnosis including CKD during ICU was based on the International Classification of Diseases, Ninth Revision (ICD-9) codes that were documented by hospital staffs when patients were discharged. Due to many duplicate record values, the blood biochemical tests including blood albumin and other indicators of the first (1st), maximum (max) and minimum (min) recorded values were used and further analyzed. Finally, these 925 CKD patients who also had no acute kidney injury (AKI) diagnosis during ICU based on ICD-9 codes, were enrolled into our cohort study. The
detailed inclusion for these CKD patients is shown in Fig. 1.

**Clinical outcomes**
Clinical outcomes of our study were CV complications during ICU treatment and 1-year mortality after included patients were discharged. CV complications were defined as the diagnosis of a composite event including MI, HF or stroke during ICU according to ICD-9. The mortality information was also recorded in the MIMIC-III database. We utilized the death date minus the date of discharge to obtain survival time for each patient.

**Covariates**
Demographic characteristics and clinical variables included age, gender, insurance type, ethnicity, blood biochemistry, concomitant diseases and medications during ICU. The insurance in these CKD patients mainly came from government, medicaid, medicare, private and self-pay insurance. Ethnicity mainly contained White, Black, Asian and other. The concomitant diseases mainly included hypertension, diabetes and malignant tumor. The medication during ICU mainly included albumin, β receptor blocker (βRB), statins and heparin.

**Statistical analysis**
In all statistical analyses, EmpowerStats 3.0 was used. To infer the association between blood albumin level and clinical outcomes in CKD patients, multivariate regression model was applied to estimate the independent causal effect of blood albumin on CV complications and 1-year mortality by adjusting for the other clinical variables related to the exposure or outcome in our study. Three logistic regression models were established: Model 1 adjusted for age and gender, Model 2 adjusted for age, gender, insurance and ethnicity and Model 3 adjusted for age, gender, insurance, ethnicity, hypertension, diabetes and malignant tumor. Worsening renal function often contributes to a dramatically increased CVD risk and/or short-term death in CKD patients. Therefore, we further used sensitivity analysis to investigated association of blood albumin with risk for CV complications and 1-year mortality by adding “creatinine and uric acid nitrogen” as covariate into the above three models.

Moreover, a single-factor smooth curve analysis was used for evaluating association between blood albumin and CV complications and 1-year mortality. A smoothed curve can fully explore the nonlinear relationship and find the exact “inflection point”. Then a stratification analysis used the “inflection point” of blood albumin level that patients were the highest risk of CV complications or 1-year mortality, as the stratification variable. Then, a conditional logistic regression model was performed to analyzed. \( P \) value less than 0.05 was statistically significant.

**Results**
**Characteristics of CKD patients during ICU**
After reviewing admissions in MIMIC-III database, we identified 925 CKD patients admitted to ICU and only patients’ first ICU admissions were analyzed in our study cohort (Fig. 1). The clinical features in the cohort were summarized in Table 1. The number of CV complications including HF, MI and stroke in these CKD patients were 427 (90.85%), 39 (8.30%) and 40 (8.51%), respectively. Patients with CV complications had significantly higher age, prevalence of malignant tumor, rate of used medications (βRB and statins) and 1-year mortality risk, compared with patients without CV complications. Blood biochemistry during ICU were also summarized in Additional file 1.

**Reduced blood albumin level contributed to lower risk for CV complications and higher risk for 1-year mortality**
Our logistic regression analysis revealed that reduced albumin (for albumin-1st, \( OR = 1.885, 95\% \ CI \ 1.474-2.412, \ P < 0.001; \) for albumin-max, \( OR = 1.530, 95\% \ CI \)
1.201–1.949, \( P < 0.001 \); for albumin-min, \( OR = 1.868, 95\% \text{ CI } 1.466–2.379, P < 0.001 \) levels were related to lower risk (Odds Ratio, OR) for CV complications in Model 3 after all covariates including age, gender, insurance, ethnicity, hypertension, diabetes and malignant tumor were controlled (Table 2). Instead, we found that reduced albumin (for albumin-1st, \( OR = 0.658, 95\% \text{ CI } 0.518–0.835, P < 0.001 \); for albumin-max, \( OR = 0.786, 95\% \text{ CI } 0.620–0.997, P = 0.047 \); for albumin-min, \( OR = 0.579, 95\% \text{ CI } 0.456–0.735, P < 0.001 \) levels were associated with an increased risk (OR) of 1-year mortality in Model 3 after all covariates were controlled. Worsening renal function has been confirmed to be an important contributing factor on occurrence of CV complication. Therefore, we further utilized sensitivity analysis by adding “creatinine and uric acid nitrogen” as covariate into the above models. We still observed similar results that lower blood albumin level independently contributed to reduced risk (OR) for CV complications and an increased risk (OR) for 1-year mortality respectively (Table 3).

### Curvilinear relation analysis of blood albumin with risk of CV complications and 1-year mortality risk

Single-factor smooth curve was structured by using blood albumin level as X axis and using both risks of CV complications and 1-year mortality Y axis respectively. Our results suggested a curvilinear relation on association between serum albumin levels and risk of CV complications (Fig. 2). We found the “inflection point” of blood albumin level that patients were at highest risk of CV complications was 3.4 g/dL. The almost linear relationship with a downward trend was observed on the association between blood albumin level and 1-year mortality risk, seen in Fig. 3.
Based to the “inflection point” (blood albumin level = 3.4 g/dL), we further divided all CKD patients into two groups by using albumin as categorical variable (patients with blood albumin level < 3.4 g/dL and with blood albumin level ≥ 3.4 g/dL). Our results suggested that lower albumin (for albumin-1st, OR = 2.091, 95% CI 1.420–3.079, P < 0.001; for albumin-max, OR = 1.801, 95% CI 1.155–2.809, P = 0.009; for albumin-min, OR = 1.985, 95% CI 1.417–2.780, P < 0.001) levels still contributed to a reduced risk (OR) for CV complications after all covariates were adjusted in patients with blood albumin level < 3.4 g/dL (Table 4). Similarly, we still observed that lower albumin (for albumin-1st, OR = 0.610, 95% CI 0.419–0.835, P = 0.010; for albumin-max, OR = 0.508, 95% CI 0.324–0.796, P = 0.003; for albumin-min, OR = 0.566, 95% CI 0.406–0.788, P < 0.001) levels still contributed to with an increased risk (OR) of 1-year mortality after these covariates were adjusted in patients with blood albumin level < 3.4 g/dL. However, there were not significant associations between blood albumin levels with risk (OR) of CV complications and 1-year mortality risk (OR) in patients with blood albumin level ≥ 3.4 g/dL.

Medication-related subgroup analysis for association between blood albumin level with risk of CV complications and 1-year mortality risk

Albumin therapy had an obvious modifying effect (for albumin-max, P value for interaction = 0.025; for albumin-min, P value for interaction = 0.025) on the
Subgroup analysis suggested that lower albumin (for albumin-max, OR = 0.957, 95% CI 0.582–1.572, \(P = 0.861\); for albumin-min, \(OR = 1.140, 95\% CI 0.647–2.007, P = 0.650\)) levels did not contribute to reduced risk (OR) for CV complications in patients with albumin therapy (Table 5). Consistently, albumin therapy also had an obvious modifying effect (for albumin-1st, \(P\) value for interaction = 0.009; for albumin-max, \(P\) value for interaction = 0.006; for albumin-min, \(P\) value for interaction = 0.032) on the independent association between blood albumin and 1-year mortality risk (OR). We found that reduced albumin (for albumin-1st, \(OR = 1.143, 95\% CI 0.678–1.928, P = 0.615\); for albumin-max, \(OR = 1.289, 95\% CI 0.805–2.065, P = 0.290\); for albumin-min, \(OR = 0.859, 95\% CI 0.499–1.481, P = 0.585\)) levels did not contribute to reduced 1-year mortality risk (OR) in patients with albumin therapy (Table 5). However, in patients without albumin therapy, reduced blood albumin level still contributed to lower risk (OR) for CV complications and increased risk (OR) for 1-year mortality. These results suggested that albumin therapy might
lower risk of CV complications and lower 1-year mortality risk in ICU patients with CKD. Additionally, therapy including used βRB, statins, heparin had obvious modifying effect on the independent associations, suggesting that these drugs did not improve risk of CV complications and 1-year mortality risk in these CKD patients.

Discussion

CKD patients tend to be accompanied with higher prevalence of traditional risk factors (aging, smoking, insulin resistance/diabetes, hypertension and dyslipidemia), which is particularly important to lead to atherosclerotic diseases in early stages of CKD [20, 21]. These risk factors not only contribute to the development of cardiovascular and cerebrovascular diseases, but also promote CKD progression due to their effect on kidney artery stenosis and nephrosclerosis [22]. However, high risk of CV complications in CKD can only be partially explained these traditional risk factors, as shown by data from the Cardiovascular Health Study (CHS) trials and ARIC study [23, 24]. The other specific aspects (nontraditional risk factors) in CKD have not fully been solved. For example, oxidative stress-inflammatory reaction is an important process in the progress of CKD, which has been considered to be a chronic inflammatory disease caused by various etiologies [24, 25]. Existing evidence showed that proinflammatory factors in circulating blood progressively increased with decreased renal function [26]. In our cohort study, our results showed that reduced blood levels of albumin were related to an increased risk of 1-year mortality in CKD patients, after adjustment for important identified confounders, which is consistent with the previous results that HEA sharply contributed to increased risk of all-cause mortality in other various populations. However, reduced serum levels of albumin were also associated with a lower risk for CV complications (MI, HF and stroke) during ICU among these patients.

### Table 5 Medication-related subgroup analysis for association between blood albumin level with risk of CV complications and 1-year mortality risk

| Variables   | Medications | CV complications | P value | P* | OR (95% CI) | P value | P* |
|-------------|-------------|------------------|---------|----|-------------|---------|----|
| Albumin-1st | Albumin     | 1.242 (0.718, 2.150) | 0.439   | 0.064 | 1.143 (0.678, 1.928) | 0.615   | 0.009 |
|             | NO Albumin  | 2.131 (1.605, 2.829) | <0.001  | 0.557 (0.422, 0.734) | <0.001 |
|             | βRB         | 2.173 (1.577, 2.994) | <0.001  | 0.142 | 0.737 (0.545, 0.997) | 0.048   | 0.193 |
|             | NO βRB      | 1.576 (1.055, 2.354) | 0.026   | 0.520 (0.343, 0.788) | 0.002  |
|             | Statins     | 2.417 (1.439, 4.059) | <0.001  | 0.250 | 0.573 (0.341, 0.966) | 0.036   | 0.500 |
|             | NO Statins  | 1.675 (1.256, 2.233) | <0.001  | 0.013 | 0.706 (0.536, 0.930) | 0.013   |
|             | Heparin     | 1.670 (1.213, 2.301) | 0.002   | 0.239 | 0.732 (0.533, 1.004) | 0.053   | 0.286 |
|             | NO Heparin  | 2.294 (1.338, 3.421) | <0.001  | 0.004 | 0.578 (0.398, 0.840) | 0.004   |
| Albumin-max | Albumin     | 0.957 (0.582, 1.572) | 0.861   | 0.025 | 1.289 (0.805, 2.065) | 0.290   | 0.006 |
|             | NO Albumin  | 1.847 (1.383, 2.467) | <0.001  | 0.001 | 0.628 (0.473, 0.834) | 0.001   |
|             | βRB         | 1.687 (1.228, 2.316) | 0.001   | 0.271 | 0.852 (0.627, 1.157) | 0.304   | 0.418 |
|             | NO βRB      | 1.393 (0.937, 2.070) | 0.102   | 0.687 (0.462, 1.022) | 0.064  |
|             | Statins     | 1.970 (1.171, 3.313) | 0.011   | 0.173 | 0.547 (0.318, 0.943) | 0.030   | 0.123 |
|             | NO Statins  | 1.383 (1.043, 1.835) | 0.025   | 0.341 | 0.877 (0.668, 1.150) | 0.173   |
|             | Heparin     | 1.393 (1.023, 1.896) | 0.035   | 0.447 | 0.825 (0.607, 1.122) | 0.220   | 0.73  |
|             | NO Heparin  | 1.782 (1.188, 2.671) | 0.005   | 0.181 | 0.768 (0.522, 1.130) | 0.013   |
| Albumin-min | Albumin     | 1.140 (0.647, 2.007) | 0.650   | 0.025 | 0.859 (0.499, 1.481) | 0.585   | 0.032 |
|             | NO Albumin  | 2.139 (1.619, 2.825) | <0.001  | 0.001 | 0.508 (0.385, 0.669) | <0.001  |
|             | βRB         | 2.157 (1.570, 2.962) | <0.001  | 0.162 | 0.651 (0.480, 0.884) | 0.006   | 0.156 |
|             | NO βRB      | 1.607 (1.083, 2.386) | 0.019   | 0.001 | 0.458 (0.304, 0.691) | <0.001  |
|             | Statins     | 2.165 (1.327, 3.531) | 0.002   | 0.510 | 0.419 (0.247, 0.712) | 0.001   | 0.197 |
|             | NO Statins  | 1.704 (1.277, 2.273) | <0.001  | 0.003 | 0.655 (0.497, 0.864) | 0.003   |
|             | Heparin     | 1.737 (1.247, 2.421) | 0.001   | 0.991 | 0.563 (0.402, 0.788) | <0.001  |
|             | NO Heparin  | 2.085 (1.440, 3.018) | <0.001  | 0.003 | 0.592 (0.418, 0.840) | 0.003   |

Adjusted for age, gender, insurance, ethnicity, hypertension, diabetes and malignant tumor

P* for interaction in two subgroup

CV: cardiovascular; ICU: intensive care unit; CKD: chronic kidney disease
Serum albumin has many physiological properties [27], which can carry lots of exogenous and endogenous substances including hormones, vitamins, fatty acids, inorganic ions bilirubin, drugs and other molecules. Importantly, albumin in circulating blood has been regarded as the most important antioxidant [9, 28]. Albumin contains more than 80% of total thiols in circulating blood for scavenging reactive oxygen and nitrogen species and has significantly anti-inflammatory effects on body [27, 29]. Serum albumin can also carry some substances such as nitric oxide and bilirubin, which indirectly provides additional protection against oxidative stress. Indeed, because of these protective properties of blood albumin, HAE has been regarded as a potentially independent risk factor for CVD. For instance, in a previous prospective study suggested that HAE can independently contributed to higher risk for cardiovascular \( (p = 0.037) \) and overall \( (p = 0.048) \) mortality in 734 patients with stable coronary artery disease [30]. It has been also established that HAE is an independently prognostic factor in HF patients, independent of other prognostic factors, such as B-type natriuretic peptides, renal failure and anemia [30–35]. Bonilla-Palomos et al. found that HAE was related to raised risk of in-hospital death \( (p = 0.04) \) and long-term mortality \( (p = 0.02) \), after adjusting for B-type natriuretic peptides and liver function in a observational study involving 362 patients who were hospitalized for acute systolic and diastolic HF [35]. Furthermore, there were evidence supported that HAE can be act as a strong prognostic factor for stroke in many observational studies [36–38], which supported the prognostic value of blood albumin for detecting stroke risk, irrespective of other specific or well-established risk factors. Also, HAE has been reported having a good prognostic value for predicting risks of AF, essential and primary pulmonary hypertension. Hemoglobin and serum albumin tend to decrease in patients with malignant diseases simultaneously, reduced hemoglobin levels have been demonstrated to be useful to predict the prognosis and inform the decision-making in patients with acute cardiovascular diseases [39]. In our study, our results suggested that reduced blood albumin levels (less than 3.4 g/dL) were associated with higher risk of 1-year mortality among ICU patients with CKD, while the significant association disappeared in CKD patients with albumin levels \( \geq 3.4 \text{ g/dL} \), which is consistent with previous conclusions that HAE can be regarded as good prognostic factor for predicting risk of long-term all-cause mortality [30–38]. However, we were surprised to observe that reduced albumin levels contributed to lower risk of CV complications, which is inconsistent with previous studies. This difference may be due to the fact that our study samples were obtained from ICU patients, whose life condition were poor that it affects our short-term results. Another reasonable reason is that only single CV event with one specific disease was included as the endpoint in previous studies, which is not consistent our results that a composite event including MI, AF, HF and stroke was used for analysis. Additionally, the main general population (relatively healthy participants) were included on previous studies for analyzing the relationship between albumin and prognosis, but there were few studies conducted on CKD population. Further research may be needed to verify our explanation in future.

Our results also suggested that albumin therapy had an obvious modifying effect on the independent association between blood albumin and 1-year mortality risk. Increased albumin levels did contribute to reduced 1-year mortality risk in patients without albumin therapy but not in those with albumin therapy. The beneficial effect of increased blood albumin in coronary artery disease, HF, AF, stroke and other CVD may primarily refer to its antioxidant, anti-inflammatory, antiplatelet aggregation and electrophysiological activation [40]. Generally known, serum albumin is the most abundant antioxidant in peripheral blood, and oxidative stress-inflammatory response has emerged as an important pathways linking to pathological process of various CVD [41]. Furthermore, there was study reported that oxidative stress-inflammatory response may be related to pathological development of venous thromboembolism [42]. HEA may also contribute to the worsening myocardial edema that has been observed in ischemic heart disease and HF [42–44].

In this retrospective study, we firstly included ICU individual with CKD from MIMIC-III database and reported that reduced blood albumin concentration independently contributed to higher risk of 1-year mortality and lower risk for CV complications during ICU treatment, which further expanded CKD-related studies on prediction of blood albumin for CV events and mortality risk. Interestingly, these significant associations did disappear in patients with serum levels albumin more than 3.4 g/dL. Importantly, we further observed that albumin therapy could reduce long-term mortality risk in these CKD patients. However, some limitations also need to be noted. Firstly, although renal function (blood creatinine and urea nitrogen) have been corrected in our sensitivity analysis, we did not provided unmeasured confounders such as specific clinical classification (CKD1-5) and dialysis history that were critical variables linking to CV complications and prognosis in CKD patients. Secondly, CV complications were diagnosed during ICU hospitalization in our study, while the history of CVD before admission is uncertain and may cause to outcome bias, which might explain for positive association that reduced
blood albumin contributed to lower risk of CV complications. Thirdly, the time interval between the measurement of blood albumin and the occurrence of our clinical outcomes was not clear, so we included the first, maximum and minimum values of blood albumin after entering the ICU for analysis. Fourthly, we have not included the variable “AKI”, which is extremely frequent in ICU patients who needed ICU care. The impact of AKI on this study is necessary to confirmed in the future. Fifthly, despite from different races, these ICU patients also led to a poor extrapolation of our research findings.

Conclusion
Our results firstly reported significant relationships between blood albumin levels and risk of CV complications and 1-year mortality risk, independent of renal function, malignancy and other confounding factors in ICU patients with CKD. Interestingly, these significant associations did disappear when serum levels albumin were more than 3.4 g/dL. The reducing blood albumin in HEA patients (blood albumin < 3.5 g/dL) might be a useful biomarker on predicting poor prognosis in CKD population, probably more reflecting activation of oxidative stress-multiple inflammatory mediators.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12872-022-02763-x.

Acknowledgements
Not applicable.

Author contributions
FH wrote the main manuscript text; JF, XW, HL, YS, HL, YL, TL and ZG completed data collation and validation; LG revised the final draft and supervised it. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Funding
This study was not supported by any fund.

Availability of data and materials
We performed a retrospective study involving ICU patients from MIMIC-III database with a diagnosis of CKD. The datasets generated during the current study are available in database (https://mimic.mit.edu/).

Declarations
Ethics approval and consent to participate
The institutional review boards (IRB) of Beth Israel Deaconess Medical Center (BIDMC) and Massachusetts Institute of Technology (MIT) approved the project and informed consents were exempted due to all patients’ data were anonymized before the data were obtained. Our study was consistent with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement [18]. All methods were also carried out in accordance with relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Critical Care Medicine, Mindong Hospital Affiliated to Fujian Medical University, Fuan 355000, Fujian, People’s Republic of China. 2 Cardiovascular Medicine, Mindong Hospital Affiliated to Fujian Medical University, 89 Heshan Road, Fuan 355000, Fujian, People’s Republic of China.

Received: 22 April 2022 Accepted: 13 July 2022
Published online: 18 July 2022

References
1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS ONE. 2016;11(7):e0158765.
2. Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19–28.
3. Tonelli M, Webe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034–47.
4. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT, Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2013;375(9731):2073–81.
5. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT, Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1541–52.
6. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52.
7. Roche M, Rendeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582(13):1783–7.
8. Garcia-Martinez R, Caraceni P, Bernardi M, Ginis P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836–46.
9. Nelson JJ, Liao D, Sharrett AR, Folsom AR, Chambless LE, Shahar E, Szko M, Eckfeldt J, Heiss G. Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000;151(3):468–77.
10. Djoussé L, Rothman KJ, Gullped LEA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002;106(23):2919–24.
11. Gopal DM, Kalogeropoulos AP, Georgiopoulou VV, Wang WW, Methvin A, Smith AL, Bauer DC, Newman AB, Kim L, Harris TB, Kitchevsky SB, Butler J, Health ABC Study. Serum albumin concentration and heart failure risk. The Health, Aging, and Body Composition Study. Am Heart J. 2010;160(2):279–85.
12. Mukamal KJ, Tolstrup JS, Friberg J, Grønbaek M, Jensen G. Fibrinogen and albumin levels and risk of atrial fibrillation in men and women (the Copenhagen City Heart Study). Am J Cardiol. 2002;89(7):851–7.
13. Xu WH, Dong C, Rundek T, Eknid MS, Sacco RL. Serum albumin levels are associated with cardioembolic and cryptogenic ischemic strokes: Northern Manhattan Study. Stroke. 2014;45(4):973–8.
14. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121(3):227–52.
15. Rapa SF, Di Iorio BR, Campiglia P, Heidland A, Marzocco S. Inflammation and oxidative stress in chronic kidney disease-potential therapeutic role of minerals, vitamins and plant-derived metabolites. Int J Mol Sci. 2019;21(1):263.
16. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, Gill JS, Hatly MA, Jardine AG, Landmesser U, Newby LK, Herzog CA, Cheung M, Wheeler DC, Winkelmaier WC, Marwick TH, Conference Participants. Chronic kidney disease and coronary artery disease. JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(14):1823–38.

17. Podkowir'ska A, Formanowicz D. Chronic kidney disease as oxidative stress- and inflammation-mediated cardiovascular disease. Antioxidants (Basel). 2020;9(8):752.

18. STROBE Group (2016) STROBE statement: home. http://www.strobe-statement.org/index.php?id=strobe-home.

19. Johnson AEW, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3:160035.

20. Major RW, Cheng MR, Grant RA, Shantikumar S, Brunk-NJ, Gray LJ. Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS ONE. 2018;13(3):e0192895.

21. Ortiz A, Covic A, Fiser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy WA, Rossignol P, Vanholder R, Wieczorek A, Zoccali C, London GM, Board of the EURERA-m Working Group of ERA-EDTA. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383(9931):1831–43.

22. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.

23. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarrafzadegan N, Grodins W, Kamdar A, Wang Y, Arencibia S, Kritchevsky D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 2007;115(2):158–65.

24. Radaelli F, Pajott M, Zoccali C, MJ van Geuns R, Vanholder R, Koomans H, Koomans PA, Zoccali C, van der Grond J, Patient MR, et al. Markers of inflammation and renal function in patients on peritoneal dialysis: a systematic review and meta-analysis. Nephrol Dial Transplant. 2012;27(6):2097–106.

25. Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Friend J, King AV, Wierda P, Wiecek A, London G, European Renal and Cardiovascular Medicine (EURERA-m) Working Group of the European Renal Association–European Dialysis Transplantation Association (ERA-EDTA). The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344–58.

26. Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Perthel R, Lovric K, Meisel W, Reinhoult J, et al. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study. Am J Kidney Dis. 2019;73(3):344–53.

27. Zoccali C, Vanholder R, Massy WA, Ortiz A, Sarafidis P, Dekker FW, Fiser D, Fouque D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Parati G, Rossignol P, Wieczorek A, London GM, European Renal and Cardiovascular Medicine (EURERA-m) Working Group of the European Renal Association–European Dialysis Transplantation Association (ERA-EDTA). The systemic nature of chronic kidney disease: a state-of-the-art review. J Am Coll Cardiol. 2019;74(14):1823–38.

28. Zhang Q, Lei YX, Wang Q, Jin YP, Fu RL, Geng HH, Huang LL, Wang XX, Wang PX. Serum albumin level is associated with the recurrence of acute ischemic stroke. Am J Emerg Med. 2016;34(9):1812–6.

29. Dzedzic T, Slowik A, Szczudlik A. Serum albumin level as a predictor of ischemic stroke outcome. Stroke. 2004;35(6):e156–8. doi: 10.1161/01.STR.0000126609.18735.be (Erratum in: Stroke. 2005;36(3):689).

30. Leonardi S, Gragnano F, Carrara G, Gargiulo G, Frigoli E, Vranckx P, Di Maio D, Spedicato V, Monda E, Fisani L, Fioletti V, Esposito F, Avvedimento M, Magliulo F, Leone A, Chianese F, Franzese M, Scilii M, Chiaia B, Mazzone P, Esposito G, Andò G, Calabrò P, Windecker S, Valgimigli M. Prognostic implications of declining hemoglobin content in patients hospitalized with acute coronary syndromes. J Am Coll Cardiol. 2021;77(4):375–88.

31. Kates RE, Yee YG, Hill S. Effect of albumin on the electrophysiologic stability of isolated perfused rabbit hearts. J Cardiovasc Pharmacol. 1989;13(1):168–72.

32. Munzel T, Gori T, Keaney JF, Jr, Maack C, Daiber A. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J. 2015;36(38):2555–64.

33. Aykac G, Guven R, Yeşin A, Eldağ BY, Bayindir A, Yılmaz N. The diagnostic value of oxidative/antioxidative balance parameters in venous thromboembolism. Clin Lab. 2015;61(7):765–9.

34. Verbruggen FH, Bertrand PB, Willems E, Gielen E, Mullens W, Giri S, Tang WHW, Raman SV, Verhaert D. Global myocardial oedema in advanced decompensated heart failure. Eur Heart J Cardiovasc Imaging. 2017;18(7):787–94.

35. Jeserich M, Foll D, Olschewski M, Kimmel S, Friedrich MG, Bode C, Geibel A. Evidence of myocardial oedema in patients with nonischemic dilated cardiomyopathy. Clin Cardiol. 2012;35(6):371–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions